Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacological therapy.

G P Rodgers1

  • 1Molecular and Clinical Hematology Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1822, USA.

Bailliere'S Clinical Haematology
|June 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olfactomedin 4 deletion induces colon adenocarcinoma in Apc<sup>Min/+</sup> mice.

Oncogene·2016
Same author

Expression of hGC-1 is correlated with differentiation of gastric carcinoma.

Histopathology·2007
Same author

Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study.

American journal of hematology·2002
Same author

ACC/AHA clinical competence statement on electrocardiography and ambulatory electrocardiography: A report of the ACC/AHA/ACP-ASIM task force on clinical competence (ACC/AHA Committee to develop a clinical competence statement on electrocardiography and ambulatory electrocardiography) endorsed by the International Society for Holter and noninvasive electrocardiology.

Circulation·2001
Same author

ACC/AHA clinical competence statement on electrocardiography and ambulatory electrocardiography. A report of the ACC/AHA/ACP-ASIM Task Force on Clinical Competence (ACC/AHA Committee to Develop a Clinical Competence Statement on Electrocardiography and Ambulatory Electrocardiography).

Journal of the American College of Cardiology·2001
Same author

Nitric oxide transport on sickle cell hemoglobin: where does it bind?

Free radical research·2001
Same journal

Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

Bailliere's clinical haematology·2000
Same journal

Prenatal diagnosis and screening of the haemoglobinopathies.

Bailliere's clinical haematology·2000
Same journal

Sickle cell disease: clinical management.

Bailliere's clinical haematology·2000
Same journal

Pathophysiology of sickle cell disease.

Bailliere's clinical haematology·2000
Same journal

Thalassaemia: clinical management.

Bailliere's clinical haematology·2000
Same journal

Pathophysiology of thalassaemia.

Bailliere's clinical haematology·2000
See all related articles

Sickle cell disease and beta-thalassemia treatments are improving, but specific non-toxic therapies are lacking. Pharmacological trials aim to increase fetal hemoglobin (HbF) to mitigate these severe beta-globin disorders.

Area of Science:

  • Hematology
  • Genetics
  • Pharmacology

Background:

  • Sickle cell disease (SCD) and beta-thalassemia are common inherited blood disorders.
  • These conditions cause severe anemia, organ damage, and reduced life expectancy.
  • Current treatments are limited, with bone marrow transplantation being the only widely applicable specific therapy.

Purpose of the Study:

  • To explore pharmacological approaches for treating SCD and beta-thalassemia.
  • To investigate methods for increasing fetal hemoglobin (HbF) production.
  • To predict and validate therapeutic inhibition levels for disease abrogation.

Main Methods:

  • Reviewing advancements in understanding globin gene expression.
  • Analyzing in vitro and animal models of erythroid phenotype reversal.

Related Experiment Videos

  • Conducting pharmacological trials, including the Multicenter Study of Hydroxyurea.

    • Main Results:

    • Pharmacological agents show potential to reverse erythroid cellular phenotypes.
    • Increased HbF production has been observed in patients undergoing treatment.
    • Clinical trial results support predictions for inhibiting pathogenic processes.

    Conclusions:

    • Pharmacological strategies targeting HbF production offer a promising avenue for SCD and beta-thalassemia treatment.
    • Understanding the molecular basis of these diseases enables prediction of therapeutic efficacy.
    • Further research and clinical trials are crucial for developing effective, non-toxic therapies.